康芝藥業(300086.SZ):頭孢泊肟酯片通過仿製藥一致性評價
格隆匯2月27日丨康芝藥業(300086.SZ)公佈,公司近日收到國家藥品監督管理局下發的頭孢泊肟酯片《藥品補充申請批件》,公司頭孢泊肟酯片通過仿製藥質量和療效一致性評價。
頭孢泊肟酯爲口服廣譜第三代頭孢菌素,進入體內後經非特異性酯酶水解爲頭孢泊肟發揮抗菌作用,其作用機理是通過抑制微生物細胞壁的生物合成而達殺菌作用,對革蘭氏陽性菌和陰性菌均有效,臨牀需求穩定,用於治療敏感菌引起的下列感染:
1、上呼吸道感染:例如:耳、鼻和喉部感染,包括急性中耳炎、鼻竇炎、扁2、下呼吸道感染:例如:社區獲得性肺炎、慢性支氣管炎急性發作;3、單純性泌尿道感染:例如:膀胱炎;4、單純性皮膚和皮膚軟組織感染:毛囊炎(包括膿皰性痤瘡)、癤、癰、丹毒、蜂窩織炎、淋巴管(結)炎、化膿性甲溝炎、皮下膿腫、汗腺炎、簇狀痤瘡、皮脂腺囊腫合併感染;5、急性單純性淋球菌性尿道炎和子宮頸炎,由奈瑟氏淋球菌引起的肛周炎。頭孢泊肟酯片適用於成人及兒童。
根據米內網數據庫顯示,頭孢泊肟酯片2023年全國城市公立醫院銷售額約1億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.